Evidence map›Paper›PMID 35185570›Full record

ArticleFrontiers in pharmacology2022

Creating China's Biosimilar Drugs Regulatory System: A Calculated Approach.

Jianhong Yang, Xiaoyu Zhao, Jie Li, Kejian Zhang, Zheru Zhang, Shunwen Chang, Daotian Fu, Xinhuan Lyu, Xianglin Zhang, Ying Shao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Current status and trends of anti-tumor biosimilars in China from 2019 to 2023: A cross-sectional analysis.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025
    Article
  2. Biosimilars Adoption: Recognizing and Removing the RoadBlocks.ClinicoEconomics and outcomes research : CEOR · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jianhong YangResearch center of Yeehong Business School, Shenyang Pharmaceutical University, Beijing, China.
Xiaoyu ZhaoResearch center of Yeehong Business School, Shenyang Pharmaceutical University, Beijing, China.
Jie LiOverland Pharma (Shanghai) Limited Company, Shanghai, China.
Kejian ZhangResearch center of Yeehong Business School, Shenyang Pharmaceutical University, Beijing, China.
Zheru ZhangI-Mab, Shanghai, China.
Shunwen ChangSkyline Therapeutics, Shanghai, China.
Daotian FuRemeGen, Ltd., Shandong, China.
Xinhuan LyuResearch center of Yeehong Business School, Shenyang Pharmaceutical University, Beijing, China.
Xianglin ZhangResearch center of Yeehong Business School, Shenyang Pharmaceutical University, Beijing, China.
Ying ShaoResearch center of Yeehong Business School, Shenyang Pharmaceutical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biosimilar drugefficacylaw and regulationsafetysupervision

Identifiers

PMID35185570
PMCPMC8848751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.